FY2017 EPS Estimates for Roche Holding Ltd. (RHHBY) Decreased by Analyst

Roche Holding Ltd. (OTCMKTS:RHHBY) – Research analysts at Jefferies Group cut their FY2017 EPS estimates for shares of Roche in a note issued to investors on Thursday. Jefferies Group analyst J. Holford now anticipates that the company will earn $1.96 per share for the year, down from their previous forecast of $1.97. Jefferies Group also issued estimates for Roche’s FY2018 earnings at $2.05 EPS, FY2019 earnings at $2.23 EPS, FY2020 earnings at $2.42 EPS and FY2022 earnings at $2.93 EPS.

Several other research firms have also commented on RHHBY. BNP Paribas lowered shares of Roche from a “neutral” rating to an “underperform” rating in a research note on Tuesday, September 26th. Zacks Investment Research raised shares of Roche from a “hold” rating to a “buy” rating and set a $35.00 price objective for the company in a research note on Tuesday. Cowen reaffirmed a “buy” rating and set a $38.00 price objective on shares of Roche in a research note on Tuesday, September 19th. JPMorgan Chase & Co. reaffirmed an “overweight” rating on shares of Roche in a research note on Friday, December 29th. Finally, Citigroup lowered shares of Roche from a “buy” rating to a “neutral” rating in a research note on Wednesday, October 18th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $36.50.

Shares of Roche (OTCMKTS:RHHBY) opened at $32.35 on Friday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.92 and a current ratio of 1.29. Roche has a 1 year low of $28.48 and a 1 year high of $36.82.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Parametric Portfolio Associates LLC boosted its position in Roche by 5.6% in the 3rd quarter. Parametric Portfolio Associates LLC now owns 3,806,074 shares of the company’s stock worth $121,794,000 after purchasing an additional 200,394 shares in the last quarter. Stonebridge Capital Advisors LLC purchased a new stake in Roche in the 3rd quarter worth approximately $221,000. Sterling Capital Management LLC boosted its position in Roche by 4.6% in the 3rd quarter. Sterling Capital Management LLC now owns 58,107 shares of the company’s stock worth $1,856,000 after purchasing an additional 2,535 shares in the last quarter. Patten Group Inc. boosted its position in Roche by 12.2% in the 3rd quarter. Patten Group Inc. now owns 29,741 shares of the company’s stock worth $847,000 after purchasing an additional 3,239 shares in the last quarter. Finally, Lenox Wealth Management Inc. boosted its position in Roche by 49.0% in the 3rd quarter. Lenox Wealth Management Inc. now owns 98,282 shares of the company’s stock worth $3,145,000 after purchasing an additional 32,335 shares in the last quarter. Hedge funds and other institutional investors own 0.58% of the company’s stock.

TRADEMARK VIOLATION WARNING: This article was published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this article on another domain, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this article can be viewed at https://www.chaffeybreeze.com/2018/01/05/fy2017-eps-estimates-for-roche-holding-ltd-rhhby-decreased-by-analyst.html.

About Roche

Roche Holding AG (Roche) is a research-based healthcare company. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.

Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply